



References

Aardal S, Helle KB, Elsayed S, Reed RK & Serck-Hanssen G (1993): Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. *J Neuroendocrinol* ;5:405-412.

Abdel-Gafar Y, Sleem H & Tawfik M (2002): Percutaneous ethanol injection in large size and multiple HCC: two years follow-up in 165 patients. *Med. J. Cairo University*; 70(4), suppl. II, December.

Ahn J & Flamm SL(2004): Hepatocellular carcinoma. *Dis Mon* 2004; 50: 556-573.

Amaoka N, Osada S, Kanematsu M, Imai H, Tomita H, Tokuyama Y, Sakashita F, Nonaka K, Goshima S, Kondo H & Adachi Y (2007): Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. *J Gastroenterol Hepatol*; 22: 2202-2207.

American Society of Clinical Oncology (ASCO) (2008): Understanding Tumor Markers. Accessed November 6.

Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerod OK & Waldum HL (1997): Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? *Prostate* ;30:1-6.



Arvan P & Castle D (1998): Sorting and storage during secretory granule biogenesis: looking backward and looking forward. *Biochem J* ;332:593-610.

Bacq Y, Zarka O Brechtot J et al (1996): Liver function tests in normal pregnancy : a prospective study of 103 pregnant women and 103 matched controls : *Hepatology* ; 23:1030-1036.

Banks P & Helle KB (1965):. The release of protein from the stimulated adrenal medulla. *Biochem J* ;97:40C-41C.

Baron RL & Brancatelli G (2004): Computed tomographic imaging of hepatocellular carcinoma. *Gastroenterology* ; 127: S133-S143.

Bates SE & Longo DL (1987): Use of serum tumor markers in cancer diagnosis and management. *Semin. Oncol*; 14: 102-38.

Beasley RP, Hwang LY, Lin CC & Chien CS (1981): Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. *Lancet* 1981; 2: 1129-1133.

Benvegnu L, Noventa F & Bernardinello E (2001): Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. *Gut* ;48:110-118.

Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J & Zako M (1999): Functions of cell surface



heparin sulfate proteoglycans. *Annu Rev Biochem* ; 68: 729-777.

Bhattacharya S, Siegel ER, Petersen GM, Chari ST, Suva L & Haun RS (2004): Diagnosis of Pancreatic Cancer Using Serum Proteomic Profiling. *Neoplasia*; 6:674–686.

Bialecki ES & Di Bisceglie AM (2005): Diagnosis of hepatocellular carcinoma. *HPB (Oxford)*; 7: 26-34.

Bigbee W & Herberman RB (2003): Tumor markers and immunodiagnosis. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III, eds. *Cancer Medicine*. 6th ed. Hamilton, Ontario: BC Decker; 209-220.

Blaschko H, Comline RC, Schneider FH, Silver M & Smith AD (1967): Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. *Nature*, 215:58-69.

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M & Sherman M (2001): Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. *Gut* ; 48: 251-259.

Boomsma F, Bhaggoe UM & Schalekamp MA (1995): Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. *Clin Chim Acta* ;239:57-63.



Bosman FT (1997) : Neuroendocrine cells in non-endocrine tumors :
what does it mean. *Verh Dtsh Ges Path* 81 :62 – 72 .

Bruix J & Sherman M (2005): Management of hepatocellular carcinoma. *Hepatology* ; 42: 1208-1236.

Bruix J, Castells A & Calvet X (1990): Diarrhea as a presenting symptoms of hepatocellular carcinoma . *Dig Dis Sci* ;35:681-690.

Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R & Llovet JM (2006): New aspects of diagnosis and therapy of hepatocellular carcinoma. *Oncogene* ; 25: 3848-3856.

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M & Rodes J (2000): Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* ; 35: 421-430.

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M & Rodés J (2001): Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* ; 35: 421-430.



Burtis CA & Ashwood ER (1999): editors. Tietz textbook of clinical chemistry. 3 rd ed. Philadelphia: W.B Saunders Company,. P. 1838-1856

Cadman PE, Rao F, Mahata SK & O'Connor DT (2002): Studies of the disglycemic peptide, pancreastatin, using a human forearm model. Ann N Y Acad Sci 2002;971:528-529.

Canale MP & Bravo EL(1994): Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994;78: 1139-1144.

Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E & Filmus J (2003): Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology; 125: 89-97.

Caselitz M, Masche N, Bleck JS, Gebel M, Atay Z, Stern C, Manns MP & Kubicka S (2003): Increasing sensitivity of morphological diagnosis in hepatocellular carcinoma (HCC) by combination of cytological and fine-needle histological examination after ultrasound guided fine needle biopsy. Z Gastroenterol ; 41: 559-564.

Chanat E & Huttner WB (1991): Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol;115:1505-1519.



- Chanat E, Weiss U, Huttner WB & Tooze SA (1993):** Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans-Golgi network causes its missorting to the constitutive secretory pathways. *EMBO J* ;12:2159-2168.
- Chen J, Röcken C, Treiber G, Jentsch-Ulrich K, Malfertheiner P & Ebert MP (2003):** Clinical implications of alpha-fetoprotein expression in gastric adenocarcinoma. *Dig Dis* ; 21: 357-362.
- Choi BG, Park SH & Byun JY et al (2001):** The findings of ruptured hepatocellular carcinoma on helical CT. *BR J Radiol* ;74:142-160.
- Ciesielski-Treska J, Ulrich G & Chasserot-Golaz S et al (2001):** Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. *J Biol Chem* ;276:13113-13120.
- Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D'Onofrio M, Evans DH, Filice C, Greiner L, Jäger K, Jong N, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, Nolsøe C, Piscaglia F, Ricci P, Seidel G, Skjoldbye B, Solbiati L, Thorelius L, Tranquart F, Weskott HP & Whittingham T (2008):** Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. *Ultraschall Med* ; 29: 28-44. *Clin. Liver Dis.*; 5: 87-107.



- Colagrande S, LaVilla G, Bartolucci M, Lanini F, Barletta G & Villari N (2003):** Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. *J Hepatol*; 39: 93-98.
- Colli A, Fraquelli M & Casazza G (2006):** Accuracy of ultrasonography, spiral CT, Magnetic resonance and Alpha-Phetoprotein in diagnosis of hepatocellular carcinoma: asystemic review . *AMJ Gastroenterol* ; 101 :513.
- Colman RW, Hirsh J, Marder VJ & Salzman EW (1994):** Haemostasis and Thrombosis Basic Principle and Clinical practice. J. B. Lippincott ; 41: 559-564.
- Colombo M, De Franchis R & DelNinno E et al (1991):** Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med*, 325: 675-690.
- Cool DR, Normant E & Shen F et al (1997):** Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. *Cell* ;88:73-83.
- Corti A, Ferrari R & Ceconi C (2000):**Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. *Adv Exp Med Biol* w;482:351-359.



Cosgrove D & Blomley M (2004): Liver tumors: evaluation with contrast-enhanced ultrasound. *Abdom Imaging* ; 29: 446-454.

Cosgrove D, Greiner L, Jäger K, Jong ND, Leen E, Lencioni R, Lindsell D, Martegani A, Solbiati L, Thorelius L, Tranquart F, Weskott HP & Whittingham T (2004): Guidelines for the use of contrast agents in ultrasound. January 2004. *Ultraschall Med* ; 25: 249-256.

Craig, J.R. (2003): Tumours of the liver. In: *Hepatology: a textbook of liver disease*. Zakim, D. and Boyer, T.D. (eds), fourth edition, Saunders, Philadelphia, London, New York, St. Louis Sydney Toronto p: 1355-1370.

Daniele B, Bencivenga A, Megna AS & Tinessa V (2004): Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. *Gastroenterology* ; 127: S108-S112.

Darwish AG (2006): Assessment of Clinical Significance of Serum Squamous Cell Carcinoma Antigen in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. Thesis submitted for partial fulfillment of the M.Sc. degree in tropical medicine, Faculty of medicine, Cairo University.

Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR & Edelman R (1993): Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. *Am J Trop Med Hyg* ; 49: 440-447.



Davila JA, Morgan RO, Shaib Y, McGlynn KA & El-Serag HB (2005): Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* ; 54: 533-539.

De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, Grigioni W, Alberti A, Beaugrand M & Pisi E (1995): HCV- associated liver cancer without cirrhosis. *Lancet* ; 345: 413-415.

Deftos LJ & Abrahamsson PA (1998): Granins and prostate cancer. *Urology* ;51:Suppl:141-145.

Deftos LJ, O'Connor DT, Wilson CB & Fitzgerald PA (1989): Human pituitary tumors secrete chromogranin-A. *J Clin Endocrinol Metab* ;68:869-872.

Desmoucelles C, Vaudry H, Eiden LE & Anouar Y (1999): Synergistic action of upstream elements and a promoter-proximal CRE is required for neuroendocrine cell-specific expression and second-messenger regulation of the gene encoding the human secretory protein secretogranin II. *Mol Cell Endocrinol* ;157:55-66.

DeStephano DB, Lloyd RV, Pike AM & Wilson BS (1984): Pituitary adenomas: an immunohistochemical study of hormone production and chromogranin localization. *Am J Pathol* ;116:464-472.



- Dimsdale JE, O'Connor DT, Ziegler M & Mills P (1992):*** Chromogranin A correlates with norepinephrine release rate. Life Sci ;51:519-525.
- Ding W & He XJ (2004):*** Fine needle aspiration cytology in the diagnosis of liver lesions. Hepatobiliary Pancreat Dis Int ; 3: 90-92.
- Dong ZZ, Yao DF, Zou L, Yao M, Qiu LW, Wu XH & Wu W (2007):*** [An evaluation of transforming growth factor-beta 1 in diagnosing hepatocellular carcinoma and metastasis] Zhonghua Ganzangbing Zazhi ; 15: 503-508.
- Ebara M, Ohto M & Kondo F (1989):*** Strategy for early diagnosis of hepatocellular carcinoma (HCC). Ann Acad Med Singapore ; 18: 83-89.
- Ebara M, Ohto M, Watanabe Y, Kimura K, Saisho H, Tsuchiya Y, Okuda K, Arimizu N, Kondo F & Ikehira H (1986):*** Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology ; 159: 371-377.
- El Gohary A, Hassan A, Nooman Z, Lavanchy D, Mayerat C, el Ayat A, Fawaz N, Gobran F, Ahmed M & Kawano F (1995):*** High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop ; 59: 155-161.



El-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrison TJ, el-Batanony M, Soliman el-S, Nasr S, Mokhtar N, Amer K, Scheuer PJ & Dhillon AP (1996): HCV-associated hepatocellular carcinoma without cirrhosis. *J Hepatol* ; 24: 277-285 .

El-Serag HB (2001): Epidemiology of Hepatocellular carcinoma.

El-Serag HB (2002): Hepotecellubr carcinoma: An epidemiologic view. *J Clin Gastroenterol*, 35(suppl2): 572-578.

El-Zayadi AR, Abaza H, Shawky S et al (2001): Prevalence and epidemiological features of hepatocellular carcinoma in Egypt – a single center experience. *Hepatol. Res.*; 19: 170-179.

El-Zayadi AR, Badran HM & Barakat EM et al. (2005): Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J of Gastroenterol.*; 11(33): 5193-5198.

El-Zayadi, AR, Badran HM & Barakat EM et al. (2005): Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J of Gastroenterol.*; 11(33): 5193-5198.

Endres DB & Rude RK (1999): Mineral and bone metabolism. In : *Tietz textbook of clinical chemistry*. Burtis CA, Ashwood ER, editors. 3 rd ed. Pheladelphia: W.B Saunders Company, P. 1395-1457.

Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, Mikhail NN, Abdel-Hamid A, Hifnawy T,



- Strickland GT & Loffredo CA (2005):** Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. *Int J Hyg Environ Health* 2005; 208: 329-339 .
- Fasani P, Sangiovanni A & Defasio C (1999):** High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. *Hepatology*; 29:1704.
- Fasciotto BH, Trauss CA, Greeley GH & Cohn DV (1993):** Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. *Endocrinology* ;133:461-466.
- Fattovich G (1998):** Progression of hepatitis B and C to hepatocellular carcinoma in western countries. *Hepatogastroenterol*, 45(suppl3):1206-1213.
- Ferrari L, Seregni E, Bajetta E, Martinetti A & Bombardieri E (1999):** The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. *Anticancer Res*;19:3415-3427.
- Fischer-Colbrie R, Laslop A & Kirchmair R (1995):** Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. *Prog Neurobiol*;46:49-70.
- França A, Giordano H, Trevisan M, Escanhoela C, Seva- Pereira T, Zucoloto S, Martinelli A & Soares E (2003):** Fine needle



aspiration biopsy improves the diagnostic accuracy of cut needle biopsy of focal liver lesions. *Acta Cytologica* ; 47: 332-336.

França AV, Elias Junior J, Lima BL, Martinelli AL & Carrilho FJ(2004): Diagnosis, staging and treatment of hepatocellular carcinoma. *Braz J Med Biol Res* ; 37: 1689-1705.

França AV, Elias Junior J, Lima BL, Martinelli AL & Carrilho FJ (2003): Diagnosis, staging and treatment of hepatocellular carcinoma. *Braz J Med Biol Res* ; 37: 1689-1705.

Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W & Sallam I (2000): The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* ; 355: 887-891.

Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V & Soriano V (2001): Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. *Am J Gastroenterol* ; 96: 179-183.

Gerdes HH, Rosa P & Phillips E, et al (1989):The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation. *J Biol Chem* ;264:12009-12015.



- Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P & Antonaci S (2007):** Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta ; 383: 147-152.
- Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P & Antonaci S (2005):** SCCA antigen combined with alphafetoprotein as serologic markers of HCC. Int J Cancer ; 117: 506-509.
- Giovanella L, Marelli M, Ceriani L, Giardina G, Garancini S & Colombo L (2001):** Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers ;16:268-272.
- Glombik MM, Kromer A, Salm T, Huttner WB & Gerdes HH (1999):** The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans-Golgi network to secretory granules. EMBO J ;18:1059-1070.
- Gomaa AI, Khan SA, Leen ELS, Waked I & Taylor-Robinson SD(2009):**Diagnosis of hepatocellular carcinoma. World J Gastroenterol ; 15(11): 1301-1314
- Gorr SU, Shioi J, Cohn DV(1989):**Interaction of calcium with porcine adrenal chromogranin A (secretory protein-I) and chromogranin B (secretogranin I). Am J Physiol ;257:E247-E254.



- Granberg D, Stridsberg M & Seensalu R et al (1999):** Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. *J Clin Endocrinol Metab* ;84:2712-2717.
- Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D & Morrow M (2002):** *AJCC Cancer Staging Handbook*. 6th edn. Springer-Verlag, New York, 145-153.
- Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E & Chiriva-Internati M (2007):** Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. *J Transl Med* ; 5: 3-9.
- Groopman JD, Scholl P & Wang JS (1996):** Epidemiology of human aflatoxin exposures and their relationship to liver cancer. *Prog Clin Biol Res* ; 395: 211-222
- Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiaroni M, Cerny A & Pape GR (2000):** Association of hepatitis C virus-specific CD8⁺ T cells with viral clearance in acute hepatitis C. *J Infect Dis* ; 181: 1528-1536.
- Gupta S, Bent S & Kohlwes J (2003):** Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. *Ann Intern Med* ; 139: 46-50.
- Halban PA & Irminger JC (1994):** Sorting and processing of secretory proteins. *Biochem J* ;299:1-18.



- Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP & Hwang LY (2001):** The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *J Clin Gastroenterol* ; 33: 123-126.
- Hasuike S, Ido A, Uto H, Moriuchi A, Tahara Y, Numata M, Nagata K, Hori T, Hayashi K & Tsubouchi H (2005):** Hepatocyte growth factor accelerates the proliferation of hepatic oval cells and possibly promotes the differentiation in a 2-acetylaminofluorene/partial hepatectomy model in rats. *J Gastroenterol Hepatol* ; 20: 1753-1761.
- Haydon GH & Hayes PC (1996):** Screening for hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* ; 8: 856-860.
- Heintges T & wands JR (1997):** Hepatitis C virus; epidemiology and transmission. *Hepatology*, 26:521-526.
- Helle KB (1966):** Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. *Mol Pharmacol* ;2:298-310.
- Helle KB (2000):** Vasostatins: vascular targets. *Adv Exp Med Biol* ;482:225-238.
- Hiroshima K, Iyoda A, Toyozaki T, Haga Y, Baba M, Fujisawa T, Ishikura H & Ohwada H (2002):** Alpha-fetoprotein-producing lung carcinoma: report of three cases. *Pathol Int* 2002; 52: 46-53adults. *Int J Cancer* ; 8: 374-383.



Hollett MD, Jeffrey RB, Nino-Murcia M, Jorgensen MJ & Harris DP(1995): Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms. *AJR Am J Roentgenol* ; 164: 879-884.

Hsia CC, Thorgeirsson SS & Tabor E (1994): Expression of hepatitis B surface and core antigens and transforming growth factor alpha in oval cells of the liver in patients with hepatocellular carcinoma . *J Med Virol* 43:216-221.

Hsiao RJ, Mezger MS & O'Connor DT (1990): Chromogranin A in uremia: progressive retention of immunoreactive fragments. *Kidney Int* ;37:955-964.

Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA & O'Connor DT (1990): Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. *Am J Med* ;88:607-613.

Hsiao RJ, Parmer RJ, Takiyyuddin MA & O'Connor DT(1991): Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. *Medicine (Baltimore)* ;70:33-45.

Hussain SM, Semelka RC & Mitchell DG(2002): MR imaging of hepatocellular carcinoma. *Magn Reson Imaging Clin N Am* ; 10: 31-52



Huttner WB & Natori S (1995): Regulated secretion: helper proteins for neuroendocrine secretion. *Curr Biol* ;5:242-245.

Huttner WB, Gerdes HH & Rosa P (1991): The granin (chromogranin/secretogranin) family. *Trends Biochem Sci* ;16:27-30.

Iacangelo A, Affolter HU & Eiden LE et al (1986): Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. *Nature* 323:82-86.

Iacangelo AL & Eiden LE (1995): Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. *Regul Pept* ;58:65-88

Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K & Kumada H(1994): Imaging diagnosis of small hepatocellular carcinoma. *Hepatology* ; 20: 82-87

Indian Journal of Clinical Biochemistry (2007): Tumor markers: An Overview; 22 (2) 17-31

Ischia R, Gasser RW & Fischer-Colbrie R et al (2000): Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. *J Clin Endocrinol Metab*;85:355-360.

Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H & Fischer-Colbrie R (1997): Molecular cloning and characterization of NESP55, a novel



chromogranin-like precursor of a peptide with 5-HT_{1B} receptor antagonist activity. J Biol Chem ;272:11657-11662.

Ishizuka H, Nakayama T, Matsuoka S, Gotoh I, Ogawa M, Suzuki K, Tanaka N, Tsubaki K, Ohkubo H, Arakawa Y & Okano T (1999): Prediction of the development of hepatocellular carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med ; 38: 927-931

Jacobson GK & Jacobson M (1983): Alpha-fetoprotein and human chorionic gonadotropin (HCG) in testicular germ cell tumours. Acta pathologica Microbiologica Scandinavica Series A;91: 183-190.

Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K & Nakamura T (2005): Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol ; 53: 35-69.

Johnson AM, Rohlfs EM & Silverman LM (1999): Proteins. In: Tietz textbook of clinical chemistry. Burtis CA, Ashwood ER, editors. 3rd ed. Philadelphia: W.B Saunders Company, P. 617-721.

Kailasam MT, Parmer RJ & Stone RA et al (1995): Factitious pheochromocytoma: novel mimicry by Valsalva maneuver and clues to diagnosis. Am J Hypertens ;8:651-655.



Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K & Kitano S (2008): Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. *Ann Surg Oncol* ;15: 1670-1676.

Kelly RB (1985): Pathways of protein secretion in eukaryotes. *Science* ;230:25-32.

Kensler TW, Qian GS & Chen JG et al (2003): Translational strategies for cancer prevention in liver. *Nature Reviews Cancer*; 3: 321-329.

Kew MC, Dos Santos HA & Sherlock S (1971): Diagnosis of Primary cancer of the liver, *Br Med J* ;4:408-416

Kew, MC (1989): Hepatic tumours and cysts. In: *Gastrointestinal and Liver Disease: pathophysiology, diagnosis, management*. Feldman, M.; Friedman, L.S.; and Sleisenger, M.H. (eds), 7th edition, Saunders, Philadelphia, London, New York, St. Louis, Sydney, p: 1577-1602.

Kew, MC (1996): Tumors of the liver. In: *Hepatology: A textbook of liver disease*, Zakim, D, Boyer, T (Eds), WB Saunders Company, Philadelphia , p:1513-1560.

Kew, MC (2002): Hepatic tumours and cysts. In: *Gastrointestinal and Liver Disease: pathophysiology, diagnosis, management*. Feldman, M.; Friedman, L.S.; and Sleisenger,



M.H. (eds), 7th edition, Saunders, Philadelphia, London, New York, St. Louis, Sydney, p: 1577-1602.

Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K & Satomura S (2001): Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001; 16: 105-111.

Kim CK, Lim JH & Lee WJ (2001): Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med ; 20: 99-104.

Kim T, Murakami T, Takahashi S, Tsuda K, Tomoda K, Narumi Y, Oi H, Sakon M & Nakamura H (1999): Optimal phases of dynamic CT for detecting hepatocellular carcinoma: evaluation of unenhanced and triple-phase images. AbdomImaging ; 24: 473-480

Kim T, Tao-Cheng JH, Eiden LE, Loh YP (2001): Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell ;106:499-509.

Kitao Y, Inada T & Arinami T, et al (2000): A contribution to genome-wide association studies: search for susceptibility loci for schizophrenia using DNA microsatellite markers on chromosomes 19, 20, 21 and 22. Psychiatr Genet ;10:139-143.



Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z & Fimmel CJ (2000): GP73, a novel Golgilocalized protein upregulated by viral infection. *Gene* ; 249: 53-65.

Kladney RD, Cui X, Bulla GA, Brunt EM & Fimmel CJ (2002): Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. *Hepatology* ; 35: 1431-1440.

Kong C, Gill BM & Rahimpour R et al (1998): Secretoneurin and chemoattractant receptor interactions. *J Neuroimmunol* ;88:91-98.

Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG & van der Kwast TH (1997): The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. *J Urol* ;158:171-174.

Krisch K, Buxbaum P & Horvat G, et al (1986): Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation: its application in diagnostic pathology. *Am J Pathol* ;123:100-108.

Lamberts SW, Hofland LJ & Nobels FR (2001): Neuroendocrine tumor markers. *Front Neuroendocrinol* 2001;22:309-339.

Landen M, Grenfeldt B & Davidsson P et al (1999): Reduction of chromogranin A and B but not C in the cerebrospinal fluid in



subjects with schizophrenia. *Eur Neuropsychopharmacol* ;9:311-315.

Lee P, Pincus MR & McPherson RA (2007): Diagnosis and management of cancer using serologic tumor markers. In: McPherson RA, Pincus MR, eds. *Henry's Clinical Diagnosis and Management by Laboratory Methods*. 21st ed. Philadelphia, Pa: Saunders Elsevier; 1353-1366.

Lee RW & Huttner WB (1983): Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. *J Biol Chem* ;258:11326-11334.

Leone N, Pelliicano R & Brunello F et al. (2002): Elevated serum chromogranin A in patients with hepatocellular carcinoma. *Clin Exp Med*;2:119 – 123.

Leung TWT, Tang AMY, Zee B, Lau WY, Lai PBS, Leung KL, Lau JT, Yu SC & Johnson PJ (2002): Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system. *Cancer*, 94: 1760-1769.

Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ & Pao CC (1986): Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. *Gastroenterology* ; 90: 263-267 .



Libbrecht L, Desmet V & Van damme B et al (2000):The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J hepatol 33:76-84.

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS & Furie B (1984):Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med ; 310: 1427-1431.

Lim JH, Choi D, Kim SH, Lee SJ, Lee WJ, Lim HK & Kim S (2002):Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol ; 179: 67-73.

Lim JH, Kim CK, Lee WJ, Park CK, Koh KC, Paik SW & Joh JW (2000): Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol ; 175: 693-698.

Liovet JM & Beaugrand M (2003): Hepatocellular carcinoma: present status and future prospects. J Hepatol ; 38 Suppl1: S136-S149.

Liovet JM (2005): Updated treatment of hepatocellular carcinoma. J Gastroenterol, 9:235-251.

Liu CJ & Kao JH (2007): Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc ; 70: 141-145 .



- Liu CJ & Kao JH (2007):** Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. *J Chin Med Assoc* ; 70: 141-145.
- Liu CJ, Kao JH & Chen DS (2005):** Therapeutic implications of hepatitis B virus genotypes. *Liver Int* ; 25: 1097-1107
- Loh YP, Snell CR & Cool DR(1997):** Receptor-mediated targeting of hormones to secretory granules: role of carboxypeptidase E. *Trends Endocrinol Metab* ;8:130-137.
- Lopez Hänninen E, Vogl TJ, Bechstein WO, GuckelbergerO, Neuhaus P, Lobeck H & Felix R (1998):** Biphasic spiral computed tomography for detection of hepatocellular carcinoma before resection or orthotopic liver transplantation. *Invest Radiol* ; 33: 216-221.
- Lowes KN, Brennan BA & Yeoh GC et al (1990):** Oval cell numbers in human chronic liver disease are directly related to disease severity . *Am J Pathol* 154:537-541.
- LTO, Lab Tests Online (2005):** Tumor markers. Accessed December 12.
- Lugardon K, Chasserot-Golaz S & Kieffer AE, et al (2001):** Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. *J Biol Chem* ;276:35875-35882.
- Lugardon K, Raffner R & Goumon Y, et al (2000):** Antibacterial and antifungal activities of vasostatin-1, the N-terminal



fragment of chromogranin A. J Biol Chem ;275:10745-10753.

Mahapatra NR, Mahata M & Datta AK, et al (2000): Neuroendocrine cell type-specific and inducible expression of the chromogranin B gene: crucial role of the proximal promoter. Endocrinology ;141:3668-3678.

Mahata SK, Kozak CA & Szpirer J et al (1996): Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. Genomics ;33:135-139.

Mahata SK, Mahata M, Livsey CV, Gerdes HH, Huttner WB & O'Connor DT (1999): Neuroendocrine cell type-specific and inducible expression of the secretogranin II gene: crucial role of cyclic adenosine monophosphate and serum response elements. Endocrinology ;140:739-749.

Mahata SK, Mahata M, Parmer RJ & O'Connor DT (1999): Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem ;274:2920-2928.

Mahata SK, Mahata M, Wu H, Parmer RJ & O'Connor DT (1999): Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin A biosynthesis. Neuroscience ;88:405-424.



- Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Berretta M, Alessandria I, Luca S & Motta M (2009):** Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch. Gerontol. Geriatr. 48, 213–217.
- Marrero JA(2005):** Screening tests for hepatocellular carcinoma clin liver disease, 9:235-251.
- Marrero JA, Fontana RJ & Barrat A et al (2005):** Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology; 41: 707-716.
- Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS & Block TM (2005):** GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol ; 43: 1007-1012
- Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ & Lok AS (2003):** Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology ;37: 1114-1121.
- Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, Ciafardini C, Colombob M, Peracchi M (2008):** Chromogranin A levels in chronic liver disease and hepatocellular carcinoma, Digestive and Liver Disease ;41:31–35.



- Mbikay M, Seidah NG & Chretien M (2001):** Neuroendocrine secretory protein 7B2: structure, expression and functions. *Biochem J* ;357:329-342.
- Michielsen, PP, Francque, SM & Dongan JL (2005):** Viral hepatitis and hepatocellular carcinoma. *World Journal of Surgical Oncology*; 3: 27- 40.
- Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A & Castagnetta LA (2002):** Epidemiology, risk factors, and natural history of hepatocellular carcinoma. *Ann N Y Acad Sci* ; 963: 13-20.
- Morin SH, Lim AK, Cobbold JF & Taylor-Robinson SD (2007):** Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. *World J Gastroenterol* ; 13: 5963-5970.
- Moss DW & Henderson AR (1996):** Clinical enzymology. In Burtis CA, Ashwood ER, editors. *Tietz Textbook of clinical chemistry*. 3 rd ed. Philadelphia: W.B Saunders Company, 1999. P. 617-721.
- Mouland AJ, Bevan S, White JH & Hendy GN (1994):** Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. *J Biol Biochem*, 265:6918-6926.



Munoz DG (1991): Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. *Lab Invest* ;64:826-832.

Nakajima K, Sakurai A, Katai M, Yajima H, Mori J, Katakura M, Tsuchiya S & Hashizume K (2000): Chromogranin A expression in hepatocellular carcinoma in a patient with germ line MEN 1 gene mutation. *Intern Med*; 39: 20-24.

Nanes MS, O'Connor DT & Marx SJ (1989): Plasma chromogranin-A in primary hyperparathyroidism. *J Clin Endocrinol Metab* ;69:950-955.

National Cancer Institute (2008): Tumor Markers; Questions and Answers. Accessed November 6, 2008. (Adapted from Cistola DP: Fat sites found! *Nat Struct Biol* 5[9]:751–753.

Neumann HPH, Berger DP & Sigmund G et al (1994): Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. *N Engl J Med* ;329:1531-1538.

Nihal M. El-Assaly, Naema I. El Ashry, I. Mostafa, Maged El Ghannam & Attia M (2008): Serum Chromogranin-A and Serum PIVKA-II as Useful Complementary and diagnostic Markers for HCC, *Res. J. Medicine & Med. Sci.*, 4(2): 391-401.

Nobels FR, Kwekkeboom DJ, Bouillon R & Lamberts SW (1998):Chromogranin A: its clinical value as marker of neuroendocrine tumours. *Eur J Clin Invest* ;28:431-440.



- Nolan EM, Cheung TC, Burton DW & Deftos LJ (1996):** Transcriptional regulation of the human chromogranin A gene by its 5' distal regulatory element: novel effects of orientation, structure, flanking sequences, and position on expression. *Mol Cell Endocrinol* ;124:51-62.
- O'Connor DT & Bernstein KN (1984):** Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. *N Engl J Med* ;311:764-770.
- O'Connor DT & Deftos LJ (1986):** Secretion of chromogranin A by peptide-producing endocrine neoplasms. *N Engl J Med* ;314:1145-1151.
- O'Connor DT & Frigon RP (1984):** Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. *J Biol Chem* ;259:3237-3247.
- O'Connor DT (1983):** Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. *Regul Pept* ;6:263-280.
- O'Connor DT, Burton D & Deftos LJ (1983):** Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. *Life Sci* ;33:1657-1663.



- O'Connor DT, Cervenka JH & Stone RA et al (1993):** Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease. *Neuroscience* ;56:999-1007.
- O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N & Parmer RJ (2002):** Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. *J Hypertens* ;20:1335-1345.
- O'Connor DT, Klein RL, Thureson-Klein AK & Barbosa JA(1991):** Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. *Brain Res* ;567:188-196.
- O'Connor DT, Pandlan MR, Carlton E, Cervenka JH & Hsiao RJ (1989):** Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. *Clin Chem* ;35:1631-1637.
- Ohashi I, Hanafusa K & Yoshida T (1993):** Small hepatocellular carcinomas: two-phase dynamic incremental CT in detection and evaluation. *Radiology* ; 189: 851-855.
- Okuda, K (1992):** Epidemiology of primary liver cancer. In: *Primary Liver Cancer in Japan*, Tobe, T (Ed), Springer-Verlag, Tokyo 1992. p.3-8



- Ottiger HP, Battenberg EF, Tsou AP, Bloom FE & Sutcliffe JG(1990):**1B1075: A brain- and pituitary-specific mRNA that encodes a novel chromogranin/secretogranin-like component of intracellular vesicles. J Neurosci ;10:3135-3147.
- Ozer, B, Serin E & Yilmaz U et al (2003):** Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. Turk J Gastroenterol; 14(2): 85-90.
- Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I & Bedossa P (2005):**Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology ; 41: 40-47.
- Peterson MS, Baron RL & Marsh JW et al (2000):** Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: Epidemiology and CT-Based tumor detection rate in 430 cases with surgical pathologic correlation .Radiology;217:743-749.
- Piker RA, Pont J, Pohnel R, Schtz W, Griesmacher A & Muller MM (1998):** Usefulness of chromogranin A as a marker for detectioin of relapses of carcinoid tumours. Clin Chem Lab Med;36:837-40.



Pitman MB(1998): Fine needle aspiration biopsy of the liver. Principal diagnostic challenges. Clin Lab Med ; 18: 483-506.

Pompili M, Riccardi L, Semeraro S, Orefice R, Elia F, Barbaro B, Covino M, Grieco A, Gasbarrini G & Rapaccini GL (2008): Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. Dig Liver Dis ; 40: 206-210.

Portel-Gomes GM, Grimelius L, Johansson H, Wilander E & Stridsberg M (2001): Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am. J. Surg. Pathol. 25, 1261–1267.

Quaia E (2007): Microbubble ultrasound contrast agents: an update. Eur Radiol ; 17: 1995-2008.

Rakitsky VN, Koblyakov VA & Turusov VS (2000): Nongenotoxic (epigenetic) carcinogens: pesticides as an example. A critical review. Teratog Carcinog Mutagen ; 20: 229-240.

Ranno S, Motta M, Rampello E, Risino C, Bennat E & Malaguarnera M (2006): The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 43, 17–126.

Rao F, Wessel J & Wen G (2007): Renal albumin excretion, twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertens ion. May., 49(5): 1015-31.



- Ratti S, Curnis F & Longhi R, et al (2000):** Structure-activity relationships of chromogranin A in cell adhesion: identification of an adhesion site for fibroblasts and smooth muscle cells. *J Biol Chem* ;275:29257-29263.
- Reiffen FU, Gratzl M (1986):** Chromogranins, widespread in endocrine and nervous tissue, bind Ca^{2+} . *FEBS Lett* ;195:327-330.
- Robbins S & Kumar V(1987):** Basic pathology. 4th ed. Philadelphia: WB Saunders, 1987: 598.
- Rosa P & Zanini A (1981):** Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis. II. Sulfated and glycosylated polypeptides. *Mol Cell Endocrinol* ;24:181-193.
- Roskams T, Willems M, Campos RV, Drucker DJ, Yap SH & Desmet VJ(1993):** Parathyroid hormone-related peptide expression in primary and metastatic liver tumors histopathology, 23:519-525.
- Rozansky DJ, Wu H, Tang K, Parmer RJ & O'Connor DT(1994):** Glucocorticoid activation of chromogranin A gene expression: identification and characterization of a novel glucocorticoid response element. *J Clin Invest* ;94:2357-2368
- Russell J, Gee P, Liu SM & Angeletti RH (1994):** Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. *Endocrinology* ;135:337-342.



Saar B & Kellner-Weldon F(2008): Radiological diagnosis of hepatocellular carcinoma. *Liver Int*; 28: 189-199.

Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M & Hatakeyama K (2008): Preoperative predictors of vascular invasion in hepatocellular carcinoma. *Eur J Surg Oncol* ; 34: 900-905.

Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J & Najib S (2000): Pancreastatin: biological effects and mechanisms of action. *Adv Exp Med Biol* ;482:247-262.

Sanchez-Margalet V, Lucas M & Goberna R (1996): Pancreastatin: further evidence for its consideration as a regulatory peptide. *J Mol Endocrinol* ;16:1-8.

Sanchez-Margalet V, Valle M & Lobon JA et al (1995): Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. *J Hypertens* ;13:251-258.

Sanduleanu S, De Bruine A & Stridsberg M et al (1990): Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. *Eur J Clin Invest* ;31:802-811.

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G & Romeo R et al (2004) : Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. *Gastroenterology* ;126:1005–14



Sato Y, Nakata K & Kato Y et al (1993): Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med, 328: 1802-1806.

Schuman G, Bonora R & Ceriotti F et al (2002): IFCC primary reference procedures for the management of catalytic activity concentrations of enzymes at 37°C. Part 5. Reference procedure for the measurement of catalytic concentration of Alanine Aminotransferase Clin Chem Lab Med; 40(7): 725-788.

Shapiro RS, Katz R, Mendelson DS, Halton KP, Schwartz ME & Miller CM (1996): Detection of hepatocellular carcinoma in cirrhotic patients: sensitivity of CT and ultrasonography. J Ultrasound Med ; 15: 497-502; quiz 503-504.

Shepard CW, Finelli L & Alter MJ (2005): Global epidemiology of hepatitis C virus infection. Lancet Infect Dis ; 5: 558-567.

Sherman M, Peltekian KM & Lee C (1995): Screening of hepatocellular carcinoma in a North American urban population. Hepatology; 22: 432.

Simon JP & Aunis D (1989): Biochemistry of the chromogranin A protein family. Biochem J ; 262: 1-13.

Simon JP, Bader MF & Aunis D (1988): Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci U S A ; 85: 1712-1716.



- Simonsson M, Eriksson S & Hakanson R et al (1988):** Endocrine cells in the human oxyntic mucosa: a histochemical study. Scand J Gastroenterol ;23:1089-1099.
- Sleisenger MF & Fordtran BF (2002):** Hepatic tumors and cysts Gastrointestinal and liver disease . 6 th edition, Philadelphia: W.B. Saunders.vol . 2 ; P.1577-1590.
- Sobol RE, Memoli V & Deftos LJ (1989):** Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med ;320:444-447.
- Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I & Deftos LJ (1986):** Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med ;105:698-700.
- Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS & Suh DJ (2002):** Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer ; 94: 175-180
- Spadaro, AA, Ajello C & Morace (2005):** Serum chromogranin-A in hepatocellular carcinoma. Diagnostic utility and limits. Wo rld J. Gas troenterol., 11(13): 1987-1990.
- Stabile BE, Howard TJ, Passaro E Jr & O'Connor DT (1990):** Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg ;125:451-453.



Stefaniuk P, Cianciara J & Wiercinska-Drapalo A (2010): Present and future possibilities for early diagnosis of hepatocellular carcinoma. *World J Gastroenterol* ;16:418-424.

Strickland GT (2006): Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. *Hepatology* ; 43: 915-922 .

Stridsberg M, Oberg K, Li Q, Engstrom U & Lundqvist G (1995): Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. *J Endocrinol* ;144:49-59.

Strub JM, Garcia-Sablone P & Lonning K et al (1995): Processing of chromogranin B in bovine adrenal medulla: identification of secretolytin, the endogenous, C-terminal fragment of residues 614-626 with antibacterial activity. *Eur J Biochem* ;229:356-368.

Su Q, Liu YF & Zhang JF et al (1994): Expression of insulin – like growth factor in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression . *Hepatology* 20:788-799.

Sugano S, Miyoshi K & Susuki T et al (1994): intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization .*AmJ gastroenterol* ; 89:184-199.



- Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, Tsubouchi H & Stuver SO (2006):** Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. *Cancer Epidemiol Biomarkers Prev* ; 15: 2521-2525.
- Syversen U, Halvorsen T, Marvik R & Waldum HL (1995):** Neuroendocrine differentiation in colorectal carcinomas. *Eur J Gastroenterol Hepatol* ;7:667-674.
- Syversen U, Jacobsen MB, Hanssen LE, O'Connor DT & Waldum HL(1993):** Chromogranin A and pancreastatin-like immunoreactivity in human carcinoid disease. *Eur J Gastroenterol Hepatol* ;5:1043-1050.
- Syversen U, Jacobsen MB, O'Connor DT, Ronning K & Waldum HL(1994):** Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. *Neuropeptides* ;26:201-206.
- Tajima Y, Nakajima T, Sugano I, Nagao K, Kondo Y & Saito J(1992):** Hepatocellular carcinoma containing endocrine cells. An autopsy report of triple cancer involving the liver, kidney and thyroid. *Acta Pathol Jpn*, 42: 904-910.
- Takamura Y(1993):** Diagnosis of portal vein thrombosis in patients with hepatocellular carcinoma: efficacy of color Doppler sonography compared with angiography. *AJR Am J Roentgenol* ; 160: 1279-1283.



- Takiyyuddin MA, Baron AD & Cervenka JH et al (1991):**
Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J Clin Endocrinol Metab ;72:616-622.
- Takiyyuddin MA, Cervenka JH & Sullivan PA et al (1990):** Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation ;81:185-195.
- Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP & O'Connor DT (1990):** Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab ;71:360-369.
- Takiyyuddin MA, Parmer RJ & Kailasam MT et al (1995):**
Chromogranin A in human hypertension: influence of heredity. Hypertension ;26:213-220.
- Tanaka K, Numata K, Okazaki H, Nakamura S, Inoue S & Torre GC (1998):** SCC antigen in malignant and nonmalignant squamous lesions. Tumour Biol ; 19: 517-526
- Tangkijvanich P, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P & Poovorawan Y (1999):**
Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health ; 30: 110-114.



Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ & Barchas JD (1996): Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. *Nature* ;324:476-478.

Taupenot L, Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Aunis D & Bader MF (1996): Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. *Neuroscience* ;72:377-389.

Taupenot L, Mahata M, Mahata SK & O'Connor DT (1999): Time-dependent effects of the neuropeptide PACAP on catecholamine secretion: stimulation and desensitization. *Hypertension* ;34:1152-1162.

Taupenot L, Mahata SK, Wu H & O'Connor DT (1998): Peptidergic activation of transcription and secretion in chromaffin cells: cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). *J Clin Invest* ;101:863-876.

Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G & Lee C (1994): The progression of HCV-associated liver disease in a cohort of haemophilic patients. *Br J Haematol* ; 87: 555-556.

Thomas L (1998): Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft ; P. 241-247.

Thomas L (1998): Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft ; P. 374-377.



Thomas L (1998): Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft ; P. 30-40.

Thomas L (1998): Clinical laboratory diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft ; P. 192-202.

Tong MJ, Blatt LM & Kao VW (2001): Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol ; 16: 553-559.

Tooze SA, Martens GJ & Huttner WB (2001): Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol ;11:116-122.

Tropea, F, Baldari S, Restifo G, Fiorillo MT, Surace P & Herberg A (2006): Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin. Drug Invest. 26, 715–722.

Tsai SL, Liaw YF, Chen MH, Huang CY & Kuo GC (1997): Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology ; 25: 449-458.

Tsao KC & Wu JT (2001): Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta ;313:21-29.

Uhlendorf V, Scholle FD & Reinhardt M (2000): Acoustic behaviour of current ultrasound contrast agents. Ultrasonics ; 38: 81-86.



- Ulmer SC (2000):** Hepatocellular carcinoma: a concise guide to its status and management. *Postgrad. Med.*; 107(5): 117-24.
- Velazquez RE, Rodriguez M, Navascues CA, Linares A, Perez R, sotorrios N, Martinez I & Rodrigo L (2003):** Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, *Hepatology*, 37:520-527.
- Videen JS, Mezger MS, Chang YM & O'Connor DT (1992):** Calcium and catecholamine interactions with adrenal chromogranins: comparison of driving forces in binding and aggregation. *J Biol Chem* ;267:3066-3073.
- Virji MA, Mercer DW & Herberman RB (1988):** Tumor Markers and their measurements. *Pathol Res Pract*; 183:95-98
- Wand GS, Takiyyuddin M, O'Connor DT & Levine MA (1991):** A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of proopiomelanocortin secretion. *Endocrinology* ;128:1345-1351.
- Wands JR (2004):** Prevention of hepatocellular carcinoma. *N. Engl. J. Med.*; 351(15): 1567-1570.
- Watkinson A & Dockray GJ (1992):** Functional control of chromogranin A and B concentrations in the body of the rat stomach. *Regul Pept* ;40:51-61.
- Weitz IC & Liebman HA (1993):** Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a criticalreview. *Hepatology* ; 18: 990-997.



Wiedenmann B & Huttner WB (1989): Synaptophysin and chromogranins/secretogranins– widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. *Virchows. Arch. B. Cell. Pathol. Incl. Mol. Pathol.* 58, 95–121.

William MS, Richard G, Kimberly KA, Jerry G, Scott HK, William FS & Philip PT (1986): Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen assays in detecting cancer of the Pancreas. *Gastroenterology*; 90:343-9.

Winkler H & Fischer-Colbrie R (1992): The chromogranins A and B: the first 25 years and future perspectives. *Neuroscience* ;49:497-528.

Wright LM, Kreikemeier JT & Fimmel CJ (2007): A concise review of serum markers for hepatocellular cancer. *Cancer Detect Prev* ; 31: 35-44.

Wu H, Mahata SK, Mahata M, Webster NJ, Parmer RJ & O'Connor DT (1995): A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. *J Clin Invest* ;96:568-578.

Wu H, Rozansky DJ, Webster NJ & O'Connor DT (1994): Cell type-specific gene expression in the neuroendocrine system: a neuroendocrine-specific regulatory element in the promoter



of chromogranin A, a ubiquitous secretory granule core protein. *J Clin Invest* ;94:118-129.

Wu JT, Erickson AJ, Tsao KC, Wu TL & Sun CF (2000): Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. *Ann Clin Lab Sci* ;30:175-178.

Wu TL, Chang CP, Tsao KC, Sun CF & Wu JT (1999): Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases. *J Clin Lab Anal* ;13:312-319.

Yamagami H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T, Kaneko M, Shioda A, Tanaka N & Arakawa Y (2002): Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. *Cancer* ; 95: 824-834.

Yasuhara O, Kawamata T, Aimi Y, McGeer EG & McGeer PL (1994): Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. *Neurosci Lett* ;170:13-16.

Yu SC, Yeung DT & So NM (2004): Imaging features of hepatocellular carcinoma. *Clin Radiol* ; 59: 145-156.



Yuen MF & Lai CL (2003): Screening for hepatocellular carcinoma: survival benefit and cost – effectiveness. *Annals of oncology*; 14: 1463-1467.

Yuen MF & Lai CL (2005): Serological markers of liver cancer. *Best Pract Res Clin Gastroenterol* ; 19: 91-99.

Zhang B, Tan Z & Zhang C et al(2002): Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population. *Neurosci Lett* ;323:229-233.

Zhou L, Liu J & Luo F (2006): Serum tumor markers for detection of hepatocellular carcinoma. *World J Gastroenterol* ; 12: 1175-118.